PT-141 | Bremelanotide Research Compound

Research Overview

PT-141 (Bremelanotide) is a synthetic peptide analogue of alpha-melanocyte stimulating hormone (alpha-MSH) that acts on melanocortin receptors, particularly MC3R and MC4R in the central nervous system.

Research has investigated PT-141’s mechanism through melanocortin receptor pathways and its effects on sexual arousal response in animal models. A pharmaceutical version (Vyleesi) received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women — the research compound studied here is the unformulated peptide used in laboratory research settings.

Select Published Research

Diamond LE et al. (2004). “An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide.” Psychosomatic Medicine.
Kingsberg S et al. (2019). “Bremelanotide for the treatment of hypoactive sexual desire disorder.” Obstetrics & Gynecology.

All referenced studies were conducted in controlled research settings. These citations do not constitute claims of safety or efficacy for unsupervised use.

Specifications

Format: Lyophilized powder
Purity: >99% verified by HPLC and mass spectrometry
Storage: −20°C lyophilized. Reconstituted: 4°C, use within 30 days.
Source: Domestically synthesized

Certificate of Analysis

Third-party COA available in the Lab Results tab above.